Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT07781488

A Clinical Trial to Evaluate the Effects of a Fibre Supplement on Microbiome and Gut Health

This study will evaluate the effects of the Artah Essential Fibre+ supplement on the microbiome and gut health over an 8-week period. The study is a single-arm, unblinded virtual trial enrolling 50 participants who will consume the test product daily and complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8.

A subgroup of 30 participants will provide stool samples for microbiome testing at Baseline and Week 8. All participants will provide body composition measurements using a smart scale at Baseline, Week 4, and Week 8. Secondary outcomes include participants' self-reported perceptions of the product's effects on gut health, metabolism, food cravings, appetite, and general well-being.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gut Health Abdominal Discomfort Bloating Bowel Movement Irregularity Constipation Diarrhea Dyspepsia Food Cravings Indigestion Microbiome Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89101, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • Aged 21-65
  • Experiencing issues regarding at least two of the following over the past four weeks: stomach discomfort, constipation, bowel movement regularity, indigestion, diarrhea, bloating, gas, abdominal pain, or excessive food cravings
  • Generally healthy - does not live with any uncontrolled chronic disease
  • If taking any other supplements or herbal remedies that target gut or digestive health, has been doing so for at least three months consistently, and is willing to maintain this for the duration of the study
  • Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the study
  • Resides in the United States

Exclusion criteria

  • Anyone unwilling to comply with the study protocol for the duration of the study
  • Anyone with a known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, ulcerative colitis (UC), celiac disease, or gastrointestinal tract surgeries
  • Anyone with known allergies or hypersensitivities to any supplement product ingredients, including sesame and mustard
  • Anyone planning to introduce any other new supplements, prescription medications, or herbal remedies at any point for the duration of the study
  • Anyone with chronic health conditions that could impact participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period
  • Anyone who has taken prescription antibiotics, prebiotics, synbiotics, postbiotics, and/or fiber supplements within the past three months
  • Has taken weight loss medications (like GLP-1 agonists) in the past three months
  • Anyone currently pregnant, trying to conceive, or breastfeeding
  • Anyone currently testing, or planning to test, a product during the course of the study

Treatment and study plan

Essential Fibre+

Dietary Supplement

All 50 participants receive the Artah Essential Fibre+ supplement once daily in the morning before the first meal of the day, mixed with 500ml of water. Dosing is graduated: one scoop on Days 1-3, two scoops on Days 4-6, and three scoops from Day 7 onwards for the remainder of the 8-week study period.

Primary outcomes

  1. Change in Gut Resilience Score

    Time frame: Baseline and Week 8

    Change from Baseline in Gut Resilience Score assessed via stool-based microbiome testing (Tiny Health)

  2. Change in Hydrogen Sulfide Index

    Time frame: Baseline and Week 8

    Change from Baseline in Hydrogen Sulfide Index assessed via stool-based microbiome testing (Tiny Health)

  3. Change in Firmicutes/Bacteroidota Ratio

    Time frame: Baseline and Week 8

    Change from Baseline in Firmicutes/Bacteroidota ratio assessed via stool-based microbiome testing (Tiny Health)

  4. Change in Hexa-LPS Index

    Time frame: Baseline and Week 8

    Change from Baseline in Hexa-LPS Index assessed via stool-based microbiome testing (Tiny Health)

  5. Change in Mucus Degradation Index

    Time frame: Baseline and Week 8

    Change from Baseline in Mucus Degradation Index assessed via stool-based microbiome testing (Tiny Health)

  6. Change in Prevotella Abundance

    Time frame: Baseline and Week 8

    Change from Baseline in Prevotella abundance assessed via stool-based microbiome testing (Tiny Health)

  7. Change in Bacteroides Abundance

    Time frame: Baseline and Week 8

    Change from Baseline in Bacteroides abundance assessed via stool-based microbiome testing (Tiny Health)

  8. Change in Abundance Index

    Time frame: Baseline and Week 8

    Change from Baseline in Abundance Index assessed via stool-based microbiome testing (Tiny Health)

  9. Change in Richness Index

    Time frame: Baseline and Week 8

    Change from Baseline in Richness Index assessed via stool-based microbiome testing (Tiny Health)

  10. Change in Proteobacteria/Actinobacteriota Ratio

    Time frame: Baseline and Week 8

    Change from Baseline in Proteobacteria/Actinobacteriota ratio assessed via stool-based microbiome testing (Tiny Health)

  11. Change in Butyrate Level

    Time frame: Baseline and Week 8

    Change from Baseline in Butyrate level assessed via stool-based microbiome testing (Tiny Health)

  12. Change in Acetate Level

    Time frame: Baseline and Week 8

    Change from Baseline in Acetate level assessed via stool-based microbiome testing (Tiny Health)

  13. Change in Propionate Level

    Time frame: Baseline and Week 8

    Change from Baseline in Propionate level assessed via stool-based microbiome testing (Tiny Health)

Secondary outcomes

  1. Change in Self-Reported Indigestion

    Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8

    Change from Baseline in participant-reported indigestion assessed via self-report questionnaire

  2. Change in Self-Reported Bloating

    Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8

    Change from Baseline in participant-reported bloating assessed via self-report questionnaire

  3. Change in Self-Reported Bowel Movement Frequency

    Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8

    Change from Baseline in participant-reported bowel movement frequency assessed via self-report questionnaire

  4. Change in Self-Reported Food Cravings

    Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8

    Change from Baseline in participant-reported food cravings assessed via self-report questionnaire

  5. Change in Self-Reported Overall Mood

    Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8

    Change from Baseline in participant-reported overall mood assessed via self-report questionnaire

Sponsors and collaborators

Lead sponsor

Artah Nutrition Limited

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 24, 2026
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.